Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of TS-172 in healthy adults
NCT06596356Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TS-172 in hyperphosphatemia, sponsored by Taisho Pharmaceutical. Primary endpoints: Radioactivity concentration in whole blood and plasma up to 240 hours, Cumulative urinary and fecal recovery of total radioactivity up to 240 hours and 3 more. Started Sep 2024; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06596356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596356.